About this trial
This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET. The drug will be given intravenously once every 8 weeks for a total of up to 4 doses over 8 months in patients aged 4 to \<12 years (Phase I) or 12 to \</=39 years (Phase II) to test its safety and efficacy, respectively.
Funding Source - FDA OOPD (grant number FD-R-0532-01)
Eligibility criteria
Qualifiers
None
Disqualifiers
Screening Criteria
Eligibility Criteria
Phase I Age Patient must be ≥ 4 and <12 years of age at the time of enrollment. Disease Status: Patients who participate in the efficacy expansion cohort must have bi-dimensionally measurable disease, defined as at least one lesion that can be accurately measured in at least two dimensions Patients with measurable extraneural disease only are also eligible.
Phase II Age Patient must be 12 to </=39 years at the time of enrollment.
Trial design
Treatments tested in this trial
- LUTATHERA® (Lutetium Lu 177 dotatate)
Treatment groups
Locations
4Sponsors and collaborators
Nationwide Children's Hospital
Lead sponsor